Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Descartes-15 by Cartesian Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
Descartes-15 is under clinical development by Cartesian Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...
Data Insights
Descartes-15 by Cartesian Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
Descartes-15 is under clinical development by Cartesian Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData,...